Karin Jordan

Active 1993–2025

68
Papers
18,057
Citations
52
h-index
65
i10-index

Citations

Citations per year for Karin Jordan1994: 2 citations1995: 3 citations1996: 2 citations1997: 5 citations1998: 7 citations1999: 3 citations2000: 5 citations2001: 2 citations2002: 3 citations2003: 1 citations2004: 1 citations2005: 2 citations2006: 3 citations2007: 14 citations2008: 16 citations2009: 11 citations2010: 28 citations2011: 21 citations2012: 32 citations2013: 61 citations2014: 64 citations2015: 81 citations2016: 45 citations2017: 80 citations2018: 102 citations2019: 458 citations2020: 656 citations2021: 739 citations2022: 597 citations2023: 524 citations2024: 870 citations2025: 376 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,350 citing papers, 16.8% of this breakdownChina: 719 citing papers, 9% of this breakdownItaly: 612 citing papers, 7.6% of this breakdownUnited Kingdom: 509 citing papers, 6.3% of this breakdownGermany: 421 citing papers, 5.3% of this breakdownFrance: 375 citing papers, 4.7% of this breakdownSpain: 305 citing papers, 3.8% of this breakdownJapan: 288 citing papers, 3.6% of this breakdownCanada: 287 citing papers, 3.6% of this breakdownNetherlands: 264 citing papers, 3.3% of this breakdownSwitzerland: 258 citing papers, 3.2% of this breakdownAustralia: 241 citing papers, 3% of this breakdown
0%16.8%Other 29.8%

Fields

  • Medicine87.3%
  • Biochemistry, Genetics and Molecular Biology6.6%
  • Immunology and Microbiology1.4%
  • Neuroscience0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Engineering0.5%
  • Other2.5%

Topics

  • Cancer Immunotherapy and Biomarkers9.4%
  • Colorectal Cancer Treatments and Studies3.3%
  • CAR-T cell therapy research3.3%
  • Chemotherapy-induced cardiotoxicity and mitigation2.8%
  • Cancer survivorship and care2.6%
  • Nausea and vomiting management2.5%
  • Other76.1%

Coauthors

All papers

Open in search
  1. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , - Annals of Oncology 2022 cited by 1,154

  2. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

    Authors: , , , , , , - Annals of Oncology 2020 cited by 487

  3. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 1,003

  4. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , - Annals of Oncology 2017 cited by 2,354

  5. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 384

  6. Bone health in cancer: ESMO Clinical Practice Guidelines

    Authors: , , , , , , , , , , , , - Annals of Oncology 2020 cited by 518

  7. Integration of oncology and palliative care: a Lancet Oncology Commission

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 834

  8. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

    Authors: , , , , , , , , , , - Annals of Oncology 2020 cited by 324

  9. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment

    Authors: , , , , , , , , - Annals of Oncology 2020 cited by 551

  10. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†

    Authors: , , , , , , , , , , , , - Annals of Oncology 2020 cited by 472

  11. Antiemetics: ASCO Guideline Update

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 457

  12. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karin Jordan, Andrey Meshcheryakov, Demetris Papamichail, Per Pfeiffer, Ioannis Souglakos, Serdar Turhal, Andrés Cervantes - Annals of Oncology 2012 cited by 1,534

  13. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ana Zilić, Karin Jordan, Florian Scotté - ESMO Open 2024 cited by 141

  14. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 635

  15. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , - Annals of Oncology 2018 cited by 430

  16. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

    Authors: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2016 cited by 580

  17. Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management

    Authors: , , - Therapeutic Advances in Medical Oncology 2009 cited by 426

  18. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines

    Authors: , , , , , , , , , - Annals of Oncology 2018 cited by 170

  19. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

    Authors: , , , , , , , , - Annals of Oncology 2017 cited by 229

  20. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dirk De Ruysscher, Elisabeth G.E. de Vries, Rebecca Dent, Jean-Yves Douillard, Domenico D’Ugo, Rafał Dziadziuszko, Corinne Faivre‐Finn, Eudald Felip, M.C. Garassino, Pilar Garrido, Nicolas Girard, Rob Glynne‐Jones, V. Golfinopoulos, John B.A.G. Haanen, E. Hamilton, Pasi A. Jänne, Karin Jordan, Ravindran Kanesvaran, S.B. Kim, Uwe G. Liebert, F. Lordick, Jean-Pascal Machiels, Olivier Michielin, T.S.K. Mok, Gilberto Morgan, Radka Obermannová, K. Park, Antonio Passaro, George Pentheroudakis, Solange Peters, Martin Reck, Romane Soler, Florian Scotté, Suresh Senan, Cristiana Sessa, Elizabeth Smyth, Ross A. Soo, Jean‐Charles Soria, Jennifer O. Spicer, Florian Strasser, Josep Tabernero, Dongling Tan, Dario Trapani, Eric Van Cutsem, Henk van Halteren, Paul E. Van Schil, Giulia Veronesi, Jing Yang, Giulia Veronesi, Jing Yang - Annals of Oncology 2020 cited by 313

  21. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

    Authors: , , , , , , , , , - Annals of Oncology 2017 cited by 112

  22. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆

    Authors: , , , , , , , - Annals of Oncology 2020 cited by 172

  23. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 89

  24. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer

    Authors: , , , , , , , - Annals of Oncology 2020 cited by 106